Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) shares fell 4.8% during trading on Tuesday . The stock traded as low as $1.00 and last traded at $1.00. 507,917 shares changed hands during trading, a decline of 72% from the average session volume of 1,785,425 shares. The stock had previously closed at $1.05.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on Adaptimmune Therapeutics in a report on Friday, December 29th. They set a "hold" rating on the stock.
Get Our Latest Report on ADAP
Adaptimmune Therapeutics Stock Performance
The stock has a fifty day moving average price of $1.41 and a 200-day moving average price of $0.92. The firm has a market capitalization of $1.02 billion, a PE ratio of -1.87 and a beta of 2.39.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.12). Adaptimmune Therapeutics had a negative net margin of 188.90% and a negative return on equity of 155.39%. The company had revenue of $0.23 million during the quarter, compared to analysts' expectations of $4.80 million. Research analysts expect that Adaptimmune Therapeutics plc will post -0.44 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC purchased a new position in shares of Adaptimmune Therapeutics in the 2nd quarter valued at $46,000. Marquette Asset Management LLC purchased a new position in Adaptimmune Therapeutics during the 3rd quarter worth $77,000. Harbor Capital Advisors Inc. grew its stake in Adaptimmune Therapeutics by 9.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company's stock worth $117,000 after buying an additional 13,317 shares during the last quarter. Key Client Fiduciary Advisors LLC grew its stake in Adaptimmune Therapeutics by 6.4% during the 4th quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company's stock worth $267,000 after buying an additional 20,295 shares during the last quarter. Finally, Acuitas Investments LLC purchased a new position in Adaptimmune Therapeutics during the 3rd quarter worth $374,000. 31.37% of the stock is currently owned by hedge funds and other institutional investors.
About Adaptimmune Therapeutics
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Further Reading
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a "Sell" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
